A new report from Lindt & Sprüngli suggests households using GLP-1 weight-loss medications are driving stronger growth in premium chocolate sales, even as some research shows overall food spending declines.

In recent years, berberine has increasingly appeared in the public sphere as a “natural way” to improve metabolism. In social media, it is sometimes compared to incretin drugs and even referred to as “plant-based Ozempic.” Such comparisons suggest a simple mechanism of action and predictable effects.

THURSDAY, March 12, 2026 — Less than 25 percent of adults with overweight or obesity without diabetes remain on any glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment after 12 months, according to a research letter published online…

(MedPage Today) — Compounded versions of tirzepatide (Mounjaro, Zepbound) containing vitamin B12 pose a potential safety risk to the public, Eli Lilly warned in an open letter on Thursday.
Following laboratory testing, the drugmaker said it uncovered…

THURSDAY, March 12, 2026 — Formulation- and sex-specific associations are seen for semaglutide use with ischemic optic neuropathy, with increased odds in men and with Wegovy use, according to a study published online March 10 in the British Journal…

Combining tirzepatide with vitamin B12, a common additive in compounded versions of the drug, yields an impurity that could alter the drug’s toxicity profile and pose safety risks to patients, the company said in an open letter.

Compounded forms of the molecule behind Eli Lilly’s metabolic blockbusters Mounjaro and Zepbound that have vitamin B12 added to them may be unsafe, Lilly said Thursday.

Lilly and its fellow GLP-1-based drugmaker Novo Nordisk have …

THURSDAY, March 12, 2026 — People frequently switch between different weight-loss drugs, swapping Ozempic for Zepbound and vice versa within the first year of treatment, a new study reports.What’s more, those patients who do swap GLP-1 drugs are mor…

The FDA is targeting telehealth marketing of GLP-1 drugs. But those companies may not be the only ones under the microscope. 

The FDA criticized the maker of Ozempic and Wegovy, Novo Nordisk, for “serious violations” related to the reporting of possible side effects linked to semaglutide, the active ingredient in the drug. NBC News’ Emily Lorsch reports on the GLP-1 drugs. 

(MedPage Today) — The FDA issued a warning letter to Novo Nordisk for failing to report and investigate potentially serious side effects associated with its popular GLP-1 medications.
In a letter dated March 5 and made public on Tuesday, the…

(MedPage Today) — GLP-1 receptor agonist use was associated with a lower risk of death in cancer patients with brain metastases and type 2 diabetes, a retrospective cohort study found.
Within 3 years of a first recorded brain metastasis, patients…

Researchers believe that high doses of semaglutide may reduce blood flow to the optic nerve, which could lead to eye stroke. Maria Korneeva/Getty Images

A new study has found that the GLP-1 drug Wegovy is linked with a higher risk of “eye stroke,” especially in men.

A Stanford study shows simple digital prompts can motivate people taking GLP-1 medications to make lifestyle changes. It’s a simple premise: What if something as small as a digital nudge could put someone on the path to healthier habits while taking GLP-1 medications?

WEDNESDAY, March 11, 2026 — Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight loss appear to be similarly effective among adults across ages, races, and starting weights, according to a review published online March 2 in JAMA…

Eli Lilly is making moves in East Asia.

The Indianapolis drugmaker said Wednesday it is earmarking $3 billion over the next decade to increase its manufacturing footprint in China. Earlier this …

Among the unreported adverse events potentially linked to Ozempic are two deaths and one case of “completed suicide,” according to an FDA inspection report.

Patients without diabetes who switched GLP-1 receptor agonist (GLP-1RA) drugs for overweight or obesity were more likely to stick with their treatment longer than those who didn’t switch, according to a new study by UT Southwestern Medical Center researchers. The findings, published in JAMA Network Open, suggest that medication changes are not uncommon among patients undergoing weight loss and that clinicians should encourage them to change GLP-1RAs if necessary to promote continuity of care.

Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of “eye stroke” (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side effect reports published in the British Journal of Ophthalmology.

‘Eye strokes’ that reduce blood flow to optic nerve likely to be side-effect of active ingredient semaglutide, says authorPatients taking Wegovy have nearly five times the risk of sudden sight loss of those on Ozempic, a large-scale study has found.Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medicines such as semaglutide (sold as Wegovy, Ozempic and Rybelsus) and tirzepetide (sold as Mounjaro) help reduce blood sugar levels, slow digestion and reduce appetite, and have been linked to reduced risks of heart attack, fewer drug overdoses and other health benefits. Continue reading…

(MedPage Today) — The obesity drug semaglutide (Wegovy) conferred a significantly higher risk of ischemic optic neuropathy (ION) than any other GLP-1 agonist, including semaglutide for diabetes (Ozempic), an analysis of FDA data showed.
In a…

The FDA issued a warning letter to Novo Nordisk — the maker of Ozempic and Wegovy — for failing to report potential side effects in patients who took its blockbuster medications.

These kitchen staples are nutrient-dense and easy to tolerate.

The FDA issued a warning letter to Novo Nordisk, the Danish drugmaker behind the diabetes and weight-loss medications Ozempic and Wegovy, over unreported potential side effects.

(MedPage Today) — GLP-1 receptor agonists may increase the risk of bone and tendon injuries, as well as conditions like osteoporosis and gout, a retrospective study suggested. (Washington Post)
Chairside HbA1c testing during routine dental visits…

TUESDAY, March 10, 2026 — Among patients eligible for metabolic and bariatric surgery (MBS), glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescriptions increased from 2018 to 2025, while MBS use decreased beginning in 2023, according to a…

Plus, news about Telix Pharmaceuticals, Laekna, Prothena, Novo Nordisk, Keymed Biosciences, AstraZeneca and f5 Therapeutics:

📊 Ascletis trumpets potential quarterly dosing of GLP-1: An investigational subcutaneous depot formulation of Ascletis’s GLP-1 drug ASC30 …

It’s the third time in recent weeks that the FDA has admonished Novo Nordisk for different practices.

A large study found that people taking GLP-1 drugs like Ozempic for diabetes were less likely to be diagnosed with substance use disorder.

A small study has found that people may be able to maintain their weight loss with fewer GLP-1 injections. Image Credit: Siluk/UCG/Universal Images Group via Getty Images

A recent small study found that reduced GLP-1 frequency may help people maintain their weight loss. 

The study shows that people who dosed as little as once every two months maintained weight loss and other improved health markers.

NORTH CHICAGO, Ill., March 9, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced positive topline results1 from the multiple ascending dose (MAD) part of its Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and…

Plainsboro, NJ, US and Bagsværd, Denmark, 09 March 2026 – Novo Nordisk today announced it has reached an agreement with telehealth company Hims & Hers that will take effect later this month. Under the terms of the agreement, Hims…

(MedPage Today) — Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see branded semaglutide (Ozempic, Wegovy) products sold through the…

MONDAY, March 9, 2026 — The use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with reduced risks for developing substance use disorders (SUDs), according to a study published online March 4 in The BMJ.Miao Cai, Ph.D., from the…

AbbVie’s foray into the obesity space is successful so far, analysts agree, as amylin analog ABBV-295 elicited as much as 9.73% weight loss at 13 weeks in the multiple ascending dose portion of a Phase 1 trial.

The companies have been embroiled in a row about compounded GLP-1 drugs that escalated to a lawsuit last month. The legal action has now been dropped and the former adversaries have struck a deal that could increase access to Novo’s obesity medicines.

(MedPage Today) — Note that some links may require registration or subscription.
GLP-1 receptor agonists may increase the risk of bone and tendon injuries along with conditions such as osteoporosis and gout, a retrospective study suggested. …